Effect of indomethacin on proteinuria in rats with autologous immune complex nephropathy.
Although non-steroidal anti-inflammatory agents have been used to reduce levels of urinary protein excretion in patients with the nephrotic syndrome, the general usefulness of these drugs in proteinuric states remains unclear. The present study was designed to confirm the efficacy and to investigate some of the mechanism/s of action of non-steroidal anti-inflammatory agents in animals with proteinuria as the result of a single form experimental renal disease. Autologous immune complex nephropathy was produced in groups of Lewis rats by the administration of autologous tubular Fx1A antigen. After marked proteinuria developed, indomethacin (8 mg/kg/day) was administered orally to one group of animals for five days while a control group received only vehicle. The level of urinary protein excretion in the indomethacin treated animals was 420 +/- 198 mg/day compared to a level of 1180 +/- 306 seen in the untreated animals (p less than 0.05). When the indomethacin-treated and control animals were compared, the reduction in proteinuria could not be found to be associated with a change in the glomerular filtration rate, urine electrolyte or osmolar excretion rates, electron microscopic appearance of the glomerular basement membrane, or a change in the glomerular permeability to neutral dextran. Treatment of animals with either sodium salicylate or lower does of indomethacin (both of which resulted also in significant falls in urinary prostaglandin E excretion rates) failed to reduce the levels of proteinuria. Thus, indomethacin was capable of reducing the levels of protein excretion in rats with autologous immune complex nephropathy although the mechanism of action of this agent remains unclear.
Kirschenbaum
M A
MA
Liebross
B A
BA
Serros
E R
ER
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D007105:Immune Complex Diseases / Q000188:drug therapy*; D007213:Indomethacin / Q000627:therapeutic use*; D007678:Kidney Glomerulus / Q000648:ultrastructure; D007684:Kidney Tubules / Q000276:immunology; D008297:Male; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000473:pathology; D011507:Proteinuria / Q000188:drug therapy*; D051381:Rats; D011917:Rats, Inbred Lew
D007213:Indomethacin